Home > Insider Trading > Filing (0001104659-22-075361)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1326190	Altimmune Inc.	ALT	Pharmaceutical Preparations (2834)	202726770

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1705905	Scot M Roberts	C/O Altimmune, Inc., 910 Clopper Road, Suite 201S Gaithersburg, MD 20878	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, Par Value $0.0001	Acquisiton	2022-06-27	25,583	$1.92	43,283	No	4	M	Direct
Common Stock, Par Value $0.0001	Acquisiton	2022-06-27	11,769	$2.60	55,052	No	4	M	Direct
Common Stock, Par Value $0.0001	Disposition	2022-06-27	37,352	$12.00	17,700	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.0001	Stock Options (option to buy)	Disposition	2022-06-27	25,583	$0.00	61,400	$1.92
Common Stock, Par Value $0.0001	Stock Options (option to buy)	Disposition	2022-06-27	11,769	$0.00	30,000	$2.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
35,817		2030-01-02	No	4	M	Direct
18,231		2029-01-02	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001	15	Indirect	Shares held by spouse of Reporting Person

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.0250, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Twenty-five percent of the shares underlying the option become vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date.
Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.